{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/crohns-disease/management/fertility-pregnancy-breastfeeding-with-crohns-disease/","result":{"pageContext":{"chapter":{"id":"b822e9cd-227b-54db-9bfd-57cf52a4e663","slug":"fertility-pregnancy-breastfeeding-with-crohns-disease","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with Crohn's disease","depth":2,"htmlHeader":"<!-- begin field 98f6f0b7-4bb2-48a0-9bc9-89137c349a5e --><h2>Scenario: Fertility, pregnancy, and breastfeeding with Crohn's disease</h2><!-- end field 98f6f0b7-4bb2-48a0-9bc9-89137c349a5e -->","summary":"Covers advice on fertility and advice on the management of Crohn's disease during pregnancy and breastfeeding.","htmlStringContent":"<!-- begin item d344ede4-e530-4559-b61b-46b653fdedbb --><!-- begin field a0b5cf6c-6ebe-45c2-b9f5-acbd00876d1c --><p>From age 13 years onwards (Female).</p><!-- end field a0b5cf6c-6ebe-45c2-b9f5-acbd00876d1c --><!-- end item d344ede4-e530-4559-b61b-46b653fdedbb -->","topic":{"id":"a55bf0e9-c7ea-505e-b7ff-5093105336e5","topicId":"7057d96d-a527-4391-84a1-c39953de3eae","topicName":"Crohn's disease","slug":"crohns-disease","lastRevised":"Last revised in August 2020","chapters":[{"id":"9c1b7d20-f572-5a3c-845f-3f4b65f646e1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b9f2bb0-4b7b-5373-ace6-15e38cc8904f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2a50fc53-dced-5bb1-83cf-20d5ce4f9e8e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a5629107-6649-5a0c-a706-90ad8bf14aa7","slug":"changes","fullItemName":"Changes"},{"id":"1a920dcd-3a15-527f-9fc2-97be951c56cc","slug":"update","fullItemName":"Update"}]},{"id":"79cdca68-ce3a-5435-bca1-8393c4d809a6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"123f065a-c1e6-59ef-a0f6-fa3212214c90","slug":"goals","fullItemName":"Goals"},{"id":"d3e5c61e-a5b9-586a-8698-69a0c0f79a5f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b41011e0-33e6-52d3-9434-5f29d0baeeb8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3bcc082-58a6-51db-a805-173080268884","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a5948dc8-4eac-58f3-8d64-68a80aeb4059","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7082be71-4889-5e95-bd5f-27917f361203","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"65c06b36-b686-57f1-be7f-6fae62c4deb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3fa00303-9d62-51cf-819b-dbad0041831e","slug":"definition","fullItemName":"Definition"},{"id":"6890604a-a1f2-5be2-94b0-d2471c85fdbc","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"0d0050de-d075-540a-9c7c-ed50c6ed1243","slug":"prevalence","fullItemName":"Prevalence"},{"id":"05aa7fe4-c9b9-51f0-bf41-2369861eba6c","slug":"complications","fullItemName":"Complications"},{"id":"67cb018a-e79e-5636-bd84-67fe57bf28c2","slug":"extra-intestinal-manifestations","fullItemName":"Extra-intestinal manifestations"},{"id":"d2c1974d-3136-58a1-b5ba-55826ab8a286","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"14a7e92b-d43e-5b64-b357-c1a4d063afb3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"32cf487b-92a9-5d33-949e-023023aede46","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"5440444f-1635-5240-bea3-54d84e6067f5","slug":"investigations","fullItemName":"Investigations"},{"id":"f7a2e718-21ad-5956-a862-8f8406ca2f8b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a49169c9-856e-51c3-94cc-76e3f02f6073","fullItemName":"Management","slug":"management","subChapters":[{"id":"c4ee1de2-52a2-5289-82bd-c3377ae84b6c","slug":"suspected-crohns-disease","fullItemName":"Scenario: Suspected Crohn's disease"},{"id":"b3e71531-764c-58b2-aa02-ece1993fb53f","slug":"confirmed-crohns-disease","fullItemName":"Scenario: Confirmed Crohn's disease"},{"id":"b822e9cd-227b-54db-9bfd-57cf52a4e663","slug":"fertility-pregnancy-breastfeeding-with-crohns-disease","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with Crohn's disease"},{"id":"9a2be3f2-65c0-5e62-9b89-9aef0f5df386","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"82ab51ab-f7f0-5464-a0dc-cb566bb3f629","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"771b1e3f-3c10-5c86-bbb4-5ff669ca2d44","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fb296c54-fd91-56fc-ab19-6fd4bb759030","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efff8f5f-5a26-5e56-a428-b3155279fcef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"420029a0-c51b-5ffc-a7f3-71940eccb5ba","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"09872916-a68f-57e9-b064-aab1b782ca32","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"dc3e796d-dda1-58f4-b43f-f4ce100ebfc2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a0922fda-b50c-5cff-8ccd-19fef4fe47f1","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a49169c9-856e-51c3-94cc-76e3f02f6073","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fb05360d-1a08-5b5e-9993-2a0a73ca516f","slug":"fertility-advice","fullItemName":"Fertility advice","depth":3,"htmlHeader":"<!-- begin field 57b6e0ee-4c08-43b5-b450-9be4b45f2b60 --><h3>What should I advise a person with Crohn's disease about fertility issues?</h3><!-- end field 57b6e0ee-4c08-43b5-b450-9be4b45f2b60 -->","summary":null,"htmlStringContent":"<!-- begin item 8a130582-9f37-489d-a912-83cd625cf085 --><!-- begin field 21852241-a39d-4be6-9112-ddb36b21ed18 --><h4>Contraception advice</h4><ul><li><strong>For women with Crohn's disease,</strong> the choice of contraceptive method may be influenced by factors such as malabsorption, surgical history, prolonged immobility, <a class=\"topic-reference internal-reference\" href=\"/topics/crohns-disease/background-information/extra-intestinal-manifestations/\">extra-intestinal manifestations</a> (such as primary sclerosing cholangitis), and associated conditions (such as osteoporosis and venous thromboembolism).<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for detailed information on contraception options for women with different co-morbidities.</li><li>The Faculty of Sexual and Reproductive Healthcare (FSRH) <a data-hyperlink-id=\"a7346a54-251d-47d3-9269-a993004ed59d\" href=\"http://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/\" target=\"_blank\">UK Medical Eligibility Criteria for contraceptive use</a> has detailed information on prescribing contraception for women with inflammatory bowel disease (IBD).</li><li>Note that:<ul><li>The efficacy of oral contraception may be reduced in women with malabsorption, small bowel disease, or a history of small bowel resection. Oral methods are unaffected by colectomy and ileostomy.</li><li>Effective contraception should be prescribed during treatment and for at least 3 months after treatment with methotrexate (in men and women), for at least 6 months after stopping infliximab, and for at least 5 months after stopping adalimumab.</li></ul></li></ul></li><li><strong>Offer sources of support and information,</strong> such as the Crohn's and Colitis UK patient information leaflet <a data-hyperlink-id=\"c49092bc-5930-4ea8-be25-a993004ed5e6\" href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/sexual-relationships-and-IBD\" target=\"_blank\">Sexual relationships and IBD</a>.</li></ul><h4>Fertility advice</h4><ul><li><strong>Advise women with Crohn's disease that:</strong><ul><li>Active disease may reduce fertility rates, and inactive disease should not affect fertility.</li><li>Women who have abdominal or pelvic sepsis, surgery or adhesions may be at increased risk of impaired tubal function.</li><li>Drug treatment with methotrexate may affect oogenesis and fertility.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/infertility/\">Infertility</a> for more information.</li></ul></li><li><strong>Advise men with Crohn's disease that:</strong><ul><li>Fertility is unlikely to be affected for most men with Crohn's disease, but pelvic surgery may lead to erectile dysfunction or ejaculatory problems. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a> for more information.</li><li>Drug treatment with sulfasalazine or methotrexate may affect spermatogenesis, however, the effect should be reversible on stopping treatment. Infliximab may affect semen quality by reducing motility in some men.</li></ul></li><li><strong>Offer sources of support and information,</strong> such as the Crohn's and Colitis UK patient information leaflet <a data-hyperlink-id=\"6ee9fb28-e49e-4484-a6ec-a993004ed5fb\" href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/fertility-and-IBD.pdf\" target=\"_blank\">Fertility and IBD</a>.</li></ul><h4>Pre-pregnancy planning</h4><ul><li><strong>Refer women and men to a gastroenterologist for pre-pregnancy counselling <em>before</em> trying to conceive, if they are planning a pregnancy.</strong> See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> for more information.<ul><li>For women, specialist drug treatment may need to be changed as some medications are teratogenic. Crohn's disease management should be optimized by the specialist, to ensure that the disease is well controlled and the person is in remission before trying to conceive. This reduces the risk of persistent disease activity and relapse during pregnancy.</li><li>For men, drug treatments that affect spermatogenesis may need to be changed to a different drug or temporarily stopped, following specialist assessment.</li></ul></li></ul><!-- end field 21852241-a39d-4be6-9112-ddb36b21ed18 --><!-- end item 8a130582-9f37-489d-a912-83cd625cf085 -->","subChapters":[{"id":"4373531a-b8db-5db6-8d0b-2bcb915501ac","slug":"basis-for-recommendation-438","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field db44cd81-0655-47c9-94c0-538f1dbb788a --><h4>Basis for recommendation</h4><!-- end field db44cd81-0655-47c9-94c0-538f1dbb788a -->","summary":null,"htmlStringContent":"<!-- begin item 438558cd-a13f-4418-bba2-4c2a47d091df --><!-- begin field 3df62c96-4434-4439-9881-a8b7aa7761f8 --><p>The recommendations on contraception, fertility, and pre-conception planning are based on the European Crohn's and Colitis Organisation (ECCO) publications <em>3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016. Part 1: diagnosis and medical management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Gomollon, 2017</a>] and <em>The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">van der Woude et al, 2015</a>], the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>], the British Society of Gastroenterology (BSG) <em>Guidelines on the management of inflammatory bowel disease in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Mowat et al, 2011</a>], and expert opinion in review articles on Crohn's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Baumgart, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Kalla, 2014</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">BNF 73, 2017</a>].</p><ul><li>The recommendations on the requirements for effective contraception when taking specialist drug treatments are based on the FSRH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">BNF 73, 2017</a>].</li><li>The risk of disease flare-ups is similar between pregnant and non-pregnant women, however, disease activity at conception influences the disease course during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Kalla, 2014</a>].</li><li>Optimum disease control is needed prior to conception and during pregnancy, as active Crohn's disease may be associated with adverse pregnancy outcomes, such as preterm labour and low birthweight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Mowat et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">van der Woude et al, 2015</a>].</li><li>The rate of voluntary childlessness is higher among women with Crohn's disease than the general population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>]. This may be secondary to concerns about the risk of adverse pregnancy outcomes, possible teratogenicity of drug treatments, and the heritability of the disease. Pre-pregnancy counselling may provide an opportunity for women to identify and discuss these issues.</li></ul><!-- end field 3df62c96-4434-4439-9881-a8b7aa7761f8 --><!-- end item 438558cd-a13f-4418-bba2-4c2a47d091df -->","subChapters":[]}]},{"id":"c7e03c05-728f-5822-bb58-e0d7a5193260","slug":"pregnancy-breastfeeding-advice","fullItemName":"Pregnancy and breastfeeding advice","depth":3,"htmlHeader":"<!-- begin field 07b597e3-3f44-49c0-b2e2-34a63d5c55ce --><h3>What advice should I give a pregnant or breastfeeding woman with Crohn's disease?</h3><!-- end field 07b597e3-3f44-49c0-b2e2-34a63d5c55ce -->","summary":null,"htmlStringContent":"<!-- begin item 021f1d60-e2f8-43e5-aefc-b8400f426014 --><!-- begin field 805a112b-73e6-447f-ae1b-65f9e6eaa723 --><p><strong>Advise women and men they need to be referred to a gastroenterologist <em>before</em> trying to conceive if they are <a class=\"topic-reference internal-reference\" href=\"/topics/crohns-disease/management/fertility-pregnancy-breastfeeding-with-crohns-disease/#fertility-advice\">planning a pregnancy</a>.</strong> See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> for more information.</p><h4>Pregnancy advice</h4><ul><li>If a woman has a planned pregnancy, ensure she is managed jointly by a gastroenterologist and obstetrician with appropriate expertise.</li><li>If a woman has an unplanned pregnancy and is prescribed:<ul><li>Methotrexate, infliximab, or adalimumab, seek immediate specialist advice from a gastroenterologist and/or a specialist in fetal medicine about stopping and changing treatment and starting folic acid supplementation.</li><li>Other medication, advise the woman to continue maintenance drug treatment, start folic acid supplementation, and arrange an urgent specialist gastroenterology review appointment to ensure that management of Crohn's disease is optimized.</li></ul></li><li>If a woman has had significant pelvic surgery, extensive perianal disease, or active rectal involvement, she may be offered elective Caesarean section to reduce the risk of potential anal sphincter damage.</li><li>Offer sources of support and information, such as the Crohn's and Colitis UK patient information leaflet <a href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/pregnancy-and-IBD.pdf\" target=\"_blank\" data-hyperlink-id=\"43498ae1-e5d7-4ca9-a2fa-a98e0019909e\">Pregnancy and IBD</a>.</li></ul><h4>Breastfeeding advice</h4><ul><li>If a woman with Crohn's disease wishes to breastfeed, seek specialist gastroenterology advice if there is any uncertainty about the safety of breastfeeding while prescribed specialist medication.<ul><li>Some drug treatments such as methotrexate, adalimumab, loperamide, ciprofloxacin, and high-dose metronidazole may need to be stopped while breastfeeding, and alternative medication started by a specialist if needed.</li></ul></li><li>If a woman experiences problems breastfeeding, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/breastfeeding-problems/\">Breastfeeding problems</a> and <a class=\"topic-reference external-reference\" href=\"/topics/mastitis-breast-abscess/\">Mastitis and breast abscess</a> for more information.</li></ul><!-- end field 805a112b-73e6-447f-ae1b-65f9e6eaa723 --><!-- end item 021f1d60-e2f8-43e5-aefc-b8400f426014 -->","subChapters":[{"id":"a291bbb0-da08-5167-a929-cfab89619c44","slug":"basis-for-recommendation-6b6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 90be8ed0-0f0f-44a1-8365-453e3682c648 --><h4>Basis for recommendation</h4><!-- end field 90be8ed0-0f0f-44a1-8365-453e3682c648 -->","summary":null,"htmlStringContent":"<!-- begin item 6b622356-4e5f-4bda-a299-a2f1e641f063 --><!-- begin field 6ff7964d-b229-4017-b8f2-ff5c7fb6bd24 --><p>The recommendations on pregnancy and breastfeeding are based on the European Crohn's and Colitis Organisation (ECCO) publication <em>The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">van der Woude et al, 2015</a>], the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>], the British Society of Gastroenterology (BSG) <em>Guidelines on the management of inflammatory bowel disease in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Mowat et al, 2011</a>], and expert opinion in a review article on Crohn's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Kalla, 2014</a>] and in the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">BNF 73, 2017</a>].</p><h5>Pregnancy advice</h5><ul><li>Adverse pregnancy outcomes are associated with active Crohn's disease, and disease flare-ups should be treated aggressively in pregnancy to reduce the risk of fetal and maternal complications. The benefits of clinical remission in pregnancy generally outweigh the risks to the fetus from specialist medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Kalla, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>].</li><li>The recommendation to ensure that women who are pregnant are managed jointly by a gastroenterologist and obstetrician is based on the FSRH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>] and the BSG clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Mowat et al, 2011</a>].</li><li>The information to seek immediate specialist advice if the woman is taking medication such as methotrexate is extrapolated from the fact that it is potentially teratogenic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">BNF 73, 2017</a>].</li><li>The information on women being offered possible Caesarean section in certain clinical situations is based on the FSRH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>] and the BSG clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">Mowat et al, 2011</a>].</li></ul><h5>Breastfeeding advice</h5><ul><li><p>The recommendations on breastfeeding are based on the FSRH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">FSRH, 2016</a>] and expert opinion in the BNF, as methotrexate is present in breast milk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">BNF 73, 2017</a>].</p></li></ul><!-- end field 6ff7964d-b229-4017-b8f2-ff5c7fb6bd24 --><!-- end item 6b622356-4e5f-4bda-a299-a2f1e641f063 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}